{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "document_type": "blogpost", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-thumbWide.jpg"}, {"height": 387, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "387", "xlarge": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/10/business/dbpix-dupont1/dbpix-dupont1-thumbStandard.jpg"}], "abstract": "In arguing against Nelson Peltz, the chemical maker has repeatedly cited what may be its strongest defense: its stock price performance and return of capital to shareholders.", "type_of_material": "Blog", "word_count": "667", "lead_paragraph": null, "pub_date": "2015-01-09T14:34:45Z", "_id": "54b02d9138f0d8367c841391", "byline": {"original": "By MICHAEL J. DE LA MERCED", "person": [{"middlename": "J.", "firstname": "Michael", "lastname": "DE LA MERCED", "rank": 1, "role": "reported", "organization": ""}]}, "source": "The New York Times", "snippet": "In arguing against Nelson Peltz, the chemical maker has repeatedly cited what may be its strongest defense: its stock price performance and return of capital to shareholders.", "web_url": "http://dealbook.nytimes.com/2015/01/09/duponts-defense-against-peltz-performance/", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "value": "Garden, Edward P", "name": "persons"}, {"rank": "2", "value": "Peltz, Nelson", "name": "persons"}, {"rank": "1", "value": "DuPont Co", "name": "organizations"}, {"rank": "2", "value": "Trian Fund Management LP", "name": "organizations"}, {"rank": "1", "value": "Boards of Directors", "name": "subject"}, {"rank": "2", "value": "Chemicals", "name": "subject"}, {"rank": "3", "value": "Shareholder Rights and Activism", "name": "subject"}], "headline": {"main": "DuPont's Main Defense Against Nelson Peltz: Performance", "kicker": "DealBook"}}